The FDA may let supplement labels carry their disclaimer once, not beside every claim

Pick up almost any supplement bottle and you will find the same sentence, in bold, somewhere near the claim on the front:

"This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Under current rules, that disclaimer has to appear wherever a company makes a health claim — the "supports immune health" style of statement that sells most of the category [s1]. On 18 December, the FDA sent a letter to the dietary supplement industry indicating it is considering changing that [s1].

What is actually being proposed

The change under consideration would require the disclaimer only once per package label, rather than alongside each claim [s1].

The agency has not proposed a rule. It has signalled that it may. Kyle Diamantas, who leads the FDA's human food division, framed it conditionally: if the agency does not identify significant concerns as it continues reviewing the available data and information regarding the request, it is likely to propose a rule amending the requirement [s1].

"The request" matters there. This is industry-initiated. The Council for Responsible Nutrition's president and chief executive, Steven Mister, argued that a single clear disclaimer tied to health claims by a symbol would be sufficient [s1].

An HHS spokesperson, Andrew Nixon, said the change would not make the warnings harder to find [s1].

Why label placement is not a trivial question

Two former and current FDA-adjacent voices raised the same mechanism from different directions.

Pieter Cohen, an associate professor at Harvard Medical School who has spent years studying what is actually in supplements, warned that reducing how often the warning must appear could lead to smaller print and less prominent placement [s1].

Scott Gottlieb, a former FDA commissioner, made a similar point: the change could allow companies to make the disclaimer less noticeable [s1].

The concern is not that the sentence disappears. It is that a requirement to repeat the disclaimer next to each claim is also, functionally, a requirement to keep it near the point where a consumer is being persuaded. Move it to a single location on the label and the disclaimer can end up somewhere the buyer never looks — legally present, practically absent.

That is an empirical claim about label reading behaviour, and neither position in this debate has published evidence attached to it in the current exchange.

The scale involved

More than 75% of Americans take at least one supplement, and roughly 100,000 different supplement products are sold online or in stores [s1].

That is the context in which a labelling detail becomes a public health question. The disclaimer is the only place on most supplement packaging where a consumer is told, in the manufacturer's own words, that the government has not assessed the claim being made. There is no equivalent signal anywhere else on the label.

What this does and does not change about the product

Nothing about the underlying regulatory structure is at stake here. Dietary supplements are not reviewed for efficacy before sale, and that is not what is being amended. The question is narrower: how many times the label has to say so.

It is also worth being precise about what the disclaimer means. It is not a warning that a product is unsafe. It is a statement that a specific claim has not been evaluated, and that the product is not intended to treat disease. Those are different things, and the sentence does both jobs at once — which is part of why its placement is contested.

What to watch

Whether the FDA actually publishes a proposed rule, and if so, what the comment file looks like. The agency's language is conditional [s1], and a signalled intention is not a rulemaking.

If a proposal does appear, the details to read for are the ones the critics named: any change to minimum type size, any change to the requirement that the disclaimer be set off from surrounding text, and whether a symbol-and-single-disclaimer model of the kind the industry has proposed [s1] is adopted as written.

This article is informational and is not medical advice. It describes a labelling requirement under consideration, not the safety or effectiveness of any product.